查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1470444

胰島素市場：按藥物、類型和應用分類 - 2024-2030 年全球預測

Insulin Market by Drug (Biologic, Biosimilar), Type (Intermediate-acting Insulin, Long-acting Insulin, Premixed Insulin), Application - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年胰島素市場規模為436.4億美元，預計2024年將達467.6億美元，2030年將達到730.3億美元，複合年成長率為7.63%。

胰島素市場包括用於治療糖尿病的各種胰島素類型的生產、分銷和消費，糖尿病是一種影響全球數百萬人的慢性代謝疾病。胰島素的主要用途是控制缺乏天然胰島素產生的 1 型糖尿病患者和胰島素釋放不足或不足的 2 型糖尿病患者的血糖值。該市場包括人類胰島素、速效和長效胰島素等現代胰島素以及生物相似藥胰島素。由於人口老化、醫療保健服務的改善、糖尿病管理意識的提高以及政府支持的擴大胰島素使用和生產的舉措，糖尿病盛行率不斷上升。另一方面，胰島素的高價格和複雜的法規環境阻礙了市場的成長。然而，隨著新型胰島素的開發和核准率的提高，生物技術的進步預計將在未來幾年推動市場成長。

主要市場統計
基準年[2023] 436.4億美元
預測年份 [2024] 467.6億美元
預測年份 [2030] 730.3億美元
複合年成長率（%） 7.63%

由於其安全性、有效性和創新特性，生物製藥預計將廣泛應用。

生物製藥（胰島素）是天然存在的胰島素，是利用重組 DNA 技術在細菌或酵母細胞等活體生物體中合成的。這些胰島素的化學性質與人類胰島素相同，並且非常模仿人體的正常胰島素反應。此外，生物胰島素由於其精確的分子結構和功能，在控制血糖值方面非常有效。生物仿製胰島素與先前核准的生物製藥胰島素相似，在安全性、純度或效力方面與參考製劑沒有臨床上的重要差異。由於與生物相似藥製造過程相關的研發成本降低，這些胰島素通常比其原廠產品便宜。生物相似藥胰島素是首選，因為與原廠生物製藥胰島素相比，它們具有成本效益。生物仿製胰島素具有相當的功效和安全性，使醫療保健系統能夠節省資金，同時又不影響患者的治療效果。生物製藥和生物類似胰島素之間的選擇取決於患者的反應、過敏反應的可能性、醫療保健系統的承受能力和可用性。這兩個領域的持續進步預計將透過提供更安全、更有效的治療方案，同時解決世界各地醫療保健系統面臨的成本挑戰，進一步改善糖尿病照護。

長效型胰島素涵蓋了較長時間的基礎作用。

中效胰島素旨在長期穩定釋放胰島素。需要更穩定、更持久的胰島素作用的糖尿病患者可能更喜歡中效胰島素。長效胰島素可提供長達 24 小時或更長時間的血糖控制，通常每天給藥一次，並且通常與其他形式的胰島素結合以實現最佳的血糖管理。預混合料胰島素結合了中效和短效或速效胰島素，可提供即時和長效血糖控制。速效胰島素給藥後立即起效，控制餐前血糖，非常適合想要快速改善高血糖的患者。短效胰島素，通常稱為常規胰島素，可在給藥後一小時內控制血糖。適合需要立即起效但作用時間比中效胰島素短的患者。

用途如果I型糖尿病患者大量使用胰島素，則必須持續監測並及時給藥。

I 型糖尿病，也稱為胰島素依賴型糖尿病或幼年型糖尿病，是一種胰臟無法產生足夠胰島素的慢性疾病。因此，I 型糖尿病患者需要外源性胰島素來調節血糖值。該群體需要具有快速吸收和峰值作用時間的速效胰島素，以模擬進餐期間的生理胰島素釋放。 II 型糖尿病是最常見的糖尿病類型，其特徵是對胰島素作用的抗性或這種荷爾蒙的產生不足。患有第 2 型糖尿病的人需要多種治療，從口服藥物到非胰島素注射或胰島素注射，這取決於疾病的進展。對於這一組，依需求選擇24小時內效果穩定的長效基礎胰島素，必要時加用Bolus控制進餐血糖。兩種類型的糖尿病都需要有效的血糖控制策略，但根據個人需求考慮特定的胰島素和輔助性治療偏好時會出現差異。

區域洞察

在美洲地區，由於主要參與者的存在、更好的醫療基礎設施以及疾病管理意識的提高，北美在胰島素市場上佔據主導地位。政府對糖尿病早期診斷和治療的舉措等因素也對這一成長做出了重大貢獻。隨著南美洲人口迅速老化，糖尿病患者數量不斷增加。墨西哥、巴西等國推出了重點防治糖尿病等非傳染性疾病的國家政策，進一步加速了該地區市場的擴張。由於醫療基礎設施和產品供應的改善，亞太地區正迅速成為胰島素的主要市場。此外，亞太地區國家正在大力投資研發，以生產具有成本效益的胰島素產品。近年來，該地區對胰島素筆和胰島素幫浦等先進胰島素輸送系統的採用激增。隨著越來越多的人意識到糖尿病管理選擇，預計亞太地區國家對胰島素和相關設備的需求將會增加。由於醫療基礎設施的改善和創新胰島素治療方法的改善，西歐的胰島素市場正在快速成長。在中東和非洲地區，醫療基礎設施的改善以及政府和國際組織的措施正在支持胰島素市場的成長。南非等國家已訂定政策，透過健康促進策略來對抗包括糖尿病在內的非傳染性疾病，這可能會推動該領域的市場成長。

FPNV定位矩陣

FPNV定位矩陣對於評估胰島素市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對胰島素市場供應商的現狀進行深入而詳細的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

本報告在以下方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4. 競爭評估和情報：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1. 胰島素市場規模及預測如何？

2.胰島素市場預測期內，有哪些產品、細分市場、應用和領域需要考慮投資？

3. 胰島素市場的技術趨勢和法規結構是什麼？

4.胰島素市場主要廠商的市場佔有率是多少？

5. 進入胰島素市場的合適型態或策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 隨著人口老化的加劇，糖尿病和肥胖症的發生率上升
      • 胰島素輸送系統的快速發展
      • 已開發國家胰島素產品優惠報銷政策
    • 抑制因素
      • 與胰島素藥物相關的高成本
    • 機會
      • 胰島素研發活動的潛在投資
      • 增加對兼容生物相似藥胰島素產品的核准
    • 任務
      • 複雜的監管環境以及患者遵守治療計劃的問題
  • 市場區隔分析
    • 藥品：安全、有效、創新的生物藥品的重要用途
    • 類型：長效胰島素在較長時間內覆蓋基礎胰島素。
    • 應用：第1型糖尿病患者大量使用胰島素，需持續監測並及時給予胰島素。
  • 市場趨勢分析
    • 成熟的醫療基礎設施和實惠產品的開發正在支持整個美洲的市場成長。
    • 政府支持提高亞太地區胰島素的可及性和利用率
    • 歐洲、中東和非洲地區的胰島素研發活動和報銷政策的可用性
  • 俄羅斯-烏克蘭衝突的累積影響
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法規結構分析

第6章按藥物分類的胰島素市場

  • 生物
  • 生物相似藥

第7章胰島素市場：依類型

  • 中效胰島素
  • 長效胰島素
  • 預混合料胰島素
  • 速效胰島素
  • 短效胰島素

第8章胰島素市場：依應用分類

  • 1型糖尿病
  • 2型糖尿病

第9章美洲胰島素市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太胰島素市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲胰島素市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 胰島素製造商Genesis投資500-6000萬美元在海得拉巴建工廠
    • 海灣製藥工業「Julfar」與 Sunshine Lake Pharma 簽署突破性協議，成為中東和北非地區生物相似藥製造的先驅
    • 賽諾菲在印度推出新的長效藥物
    • 加州和製藥公司合作生產負擔得起的胰島素
    • 諾和諾德為印度患者推出每週胰島素治療
    • ADOCIA宣布與合作夥伴通化東寶合作生物伴侶賴ChaperoneLispro一期試驗取得成功
    • Glenmark在印度推出第二型糖尿病及高抗藥性藥物，股價大漲
    • 禮來公司和 EVA Pharma 宣佈建立合作夥伴關係，以加強非洲永續獲得負擔得起的胰島素
    • 諾和諾德推出 Tresiba 類似物生物製藥胰島素，以擴大患者的購買選擇
    • Optum 和賽諾菲合作為未投保者提供低成本胰島素

第13章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-03548A2B9FF7

[199 Pages Report] The Insulin Market size was estimated at USD 43.64 billion in 2023 and expected to reach USD 46.76 billion in 2024, at a CAGR 7.63% to reach USD 73.03 billion by 2030.

The insulin market encompasses the production, distribution, and consumption of various insulin types used to treat diabetes mellitus, a chronic metabolic disorder affecting millions worldwide. The primary application of insulin is to control blood sugar levels in patients with type 1 diabetes who lack natural insulin production and those with type 2 diabetes who have developed insufficient or insufficient insulin release. The scope of this market includes human insulin, modern insulins such as rapid-acting and long-acting, and biosimilar insulins. Increasing prevalence of diabetes due to aging populations, improved access to healthcare services, increased awareness about diabetes management, and supportive government initiatives to expand the use and production of insulin. On the other hand, the high cost of insulin and the complex regulatory environment hinder the market growth. However, advancements in biotechnology, which have led to development of novel insulins and increasing approval rates, are expected to proliferate the market growth in the coming years.

KEY MARKET STATISTICS
Base Year [2023] USD 43.64 billion
Estimated Year [2024] USD 46.76 billion
Forecast Year [2030] USD 73.03 billion
CAGR (%) 7.63%

Drug: Significant use of biologic drugs due to having safety, efficacy, and innovative features

Biologic insulin is naturally occurring insulin synthesized using recombinant DNA technology in living organisms, such as bacteria or yeast cells. These insulins are chemically identical to human insulin and closely mimic the body's normal insulin response. Additionally, biological insulins demonstrate high efficacy in controlling blood sugar levels due to their precise molecular structure and function. Biosimilar insulins are similar to biologic insulins that have previously received approval and have no clinically significant variations from their reference products regarding safety, purity, or potency. These insulins are often more affordable than their branded counterparts due to reduced research and development costs associated with the biosimilars' production process. Preference for biosimilar insulin arises from its cost-effectiveness compared to branded biologic insulin options. It provides comparable efficacy and safety profiles, allowing healthcare systems to save on expenses without compromising patient outcomes. The choice between biologic or biosimilar insulin depends on patient response, potential allergic reactions, healthcare system affordability concerns, and accessibility. Continued advancements in both segments are expected to further enhance diabetes care by providing safer and more effective treatment options while addressing the cost challenges healthcare systems worldwide face.

Type: Long-acting insulins provide basal coverage for an extended duration

Intermediate-acting insulin is designed to provide a steady insulin release over an extended period. People with diabetes who require a more stable and longer-lasting insulin effect may prefer intermediate-acting insulin. Long-acting insulin offers prolonged blood sugar control, lasting up to 24 hours or more, usually administered once daily, and is often combined with other forms of insulin for optimal glucose management. Premixed insulin combines intermediate-acting and short- or rapid-acting insulins, offering both immediate and sustained blood sugar control. Rapid-acting insulin works quickly after administration, controlling blood sugar before a meal, which is ideal for patients who need rapid correction of high blood glucose levels. Short-acting insulin, commonly known as regular insulin, controls blood sugar less than an hour after administration. It is suitable for patients who require a fast onset but shorter duration of action than intermediate-acting insulins.

Application: Extensive use of insulin by type I diabetic patients requires constant monitoring and timely administration of insulin

Type I diabetes, also called insulin-dependent or juvenile diabetes, is a chronic disease described by the incapacity of the pancreas to produce adequate insulin. As a result, patients with Type I diabetes require exogenous insulin to regulate their blood glucose levels. The need-based preference for this group is fast-acting insulins that provide rapid absorption and peak action time to mimic physiological insulin release during meals. Type II diabetes is the most common form of diabetes, characterized by resistance to the effects of insulin or insufficient production of this hormone. Patients with Type II diabetes may require various treatments ranging from oral medications to non-insulin injectable drugs or insulin injections, depending on disease progression. The need-based preference for this group includes long-acting basal insulins providing steady coverage over 24 hours and additional bolus injections if required for mealtime blood sugar control. Although both types of diabetes necessitate effective blood glucose management strategies, distinctions arise when considering the preferences for specific insulins or adjunct therapies based on individual needs.

Regional Insights

In the Americas region, North America dominates the insulin market due to the presence of key players, better healthcare infrastructure, and increased awareness regarding disease management. Factors such as government initiatives for early diagnosis and treatment of diabetes are also contributing significantly to this growth. South America is witnessing rising cases of diabetes amidst its rapidly aging population. Countries such as Mexico and Brazil have introduced national policies focusing on preventing and controlling non-communicable diseases, including diabetes, further accelerating market expansion in the region. The Asia-Pacific region is fast emerging as a major market for insulin due to its improvements in healthcare infrastructure and product availability. Furthermore, APAC countries have invested heavily in research and development to produce cost-effective insulin products. In recent years, there has been a surge in the adoption of advanced insulin delivery systems, such as insulin pens and pumps, in the region. As more people become aware of diabetes management options, the demand for insulin and associated devices is projected to increase across APAC countries. Western Europe's insulin market is growing rapidly due to its well-established healthcare infrastructure and increased accessibility to innovative insulin therapies. In the Middle East and Africa region, improving healthcare infrastructure and efforts made by government and international organizations support insulin market growth. Countries such as South Africa are introducing policies to combat non-communicable diseases, including diabetes, through health promotion strategies, which could drive market growth in this area.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Insulin Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Insulin Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Insulin Market, highlighting leading vendors and their innovative profiles. These include ADOCIA, AstraZeneca PLC, Baxter International, Inc., Biocon Limited, Bioton S.A., CardioVends, Eli Lilly and Company, Eva Pharma, GeneSys Biologics, Glenmark Pharmaceuticals Ltd., Gulf Pharmaceutical Industries (Julphar), MannKind Corporation, Merck & Co., Inc., MJ Biopharm Pvt. Ltd., Novartis AG, Novo Nordisk A/S, Oramed Pharmaceuticals Inc., Pfizer Inc., Sanofi Group, Tonghua Dongbao Pharmaceutical Co., Ltd., Viatris Inc., Wockhardt Limited, and Zealand Pharma A/S.

Market Segmentation & Coverage

This research report categorizes the Insulin Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug
    • Biologic
    • Biosimilar
  • Type
    • Intermediate-acting Insulin
    • Long-acting Insulin
    • Premixed Insulin
    • Rapid-acting Insulin
    • Short-acting Insulin
  • Application
    • Type I Diabetes
    • Type II Diabetes
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Insulin Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Insulin Market?

3. What are the technology trends and regulatory frameworks in the Insulin Market?

4. What is the market share of the leading vendors in the Insulin Market?

5. Which modes and strategic moves are suitable for entering the Insulin Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidence of diabetes and obesity with increasing geriatric population
      • 5.1.1.2. Rapid development in insulin delivery systems
      • 5.1.1.3. Favorable reimbursement policies for insulin products in developed countries
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with insulin drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Potential investments in R&D activities for insulin development
      • 5.1.3.2. Rising approvals for interchangeable biosimilar insulin products
    • 5.1.4. Challenges
      • 5.1.4.1. Complex regulatory landscape and problems related to patient adherence to treatment regimens
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug: Significant use of biologic drugs due to having safety, efficacy, and innovative features
    • 5.2.2. Type: Long-acting insulins provide basal coverage for an extended duration
    • 5.2.3. Application: Extensive use of insulin by type I diabetic patients requires constant monitoring and timely administration of insulin
  • 5.3. Market Trend Analysis
    • 5.3.1. Established healthcare infrastructure and development of affordable product have supplemented market growth across the Americas
    • 5.3.2. Government support to increase accessibility and usage of insulin in APAC region
    • 5.3.3. Research & development activities and availability of reimbursement policies for insulin in the EMEA region
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework Analysis

6. Insulin Market, by Drug

  • 6.1. Introduction
  • 6.2. Biologic
  • 6.3. Biosimilar

7. Insulin Market, by Type

  • 7.1. Introduction
  • 7.2. Intermediate-acting Insulin
  • 7.3. Long-acting Insulin
  • 7.4. Premixed Insulin
  • 7.5. Rapid-acting Insulin
  • 7.6. Short-acting Insulin

8. Insulin Market, by Application

  • 8.1. Introduction
  • 8.2. Type I Diabetes
  • 8.3. Type II Diabetes

9. Americas Insulin Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Insulin Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Insulin Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Insulin Maker GeneSys to Invest USD 50-60 MN to Set Up Plant in Hyderabad
    • 12.3.2. Gulf Pharmaceutical Industries 'Julphar' Signs Landmark Agreement with Sunshine Lake Pharma to Pioneer Insulin Biosimilar Manufacturing in MENA
    • 12.3.3. Sanofi Launches New Long-Acting Insulin Drug in India
    • 12.3.4. California, Drugmaker Partner to Produce Affordable Insulin
    • 12.3.5. Novo Nordisk to Launch Once-a-Week Insulin Regime for Indian Patients
    • 12.3.6. ADOCIA Announces the Successful Phase 1 Study for BioChaperone Lispro with Partner Tonghua Dongbao
    • 12.3.7. Glenmark Launches Type 2 Diabetes and High Insulin Resistance Drug in India; Shares Jump
    • 12.3.8. Lilly and EVA Pharma Announce Collaboration to Enhance Sustainable Access to Affordable Insulin in Africa
    • 12.3.9. Novo Nordisk Launches Unbranded Biologic of Tresiba Analog Insulin to Expand Affordability Options for Patients
    • 12.3.10. Optum, Sanofi Partner on Low Cost Insulin for the Uninsured

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. INSULIN MARKET RESEARCH PROCESS
  • FIGURE 2. INSULIN MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL INSULIN MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL INSULIN MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL INSULIN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. INSULIN MARKET DYNAMICS
  • FIGURE 7. GLOBAL INSULIN MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL INSULIN MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL INSULIN MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL INSULIN MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL INSULIN MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL INSULIN MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS INSULIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS INSULIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES INSULIN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES INSULIN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC INSULIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC INSULIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA INSULIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA INSULIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. INSULIN MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. INSULIN MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. INSULIN MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL INSULIN MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL INSULIN MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL INSULIN MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL INSULIN MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL INSULIN MARKET SIZE, BY BIOLOGIC, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL INSULIN MARKET SIZE, BY BIOLOGIC, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL INSULIN MARKET SIZE, BY BIOSIMILAR, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL INSULIN MARKET SIZE, BY BIOSIMILAR, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL INSULIN MARKET SIZE, BY INTERMEDIATE-ACTING INSULIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL INSULIN MARKET SIZE, BY INTERMEDIATE-ACTING INSULIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL INSULIN MARKET SIZE, BY LONG-ACTING INSULIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL INSULIN MARKET SIZE, BY LONG-ACTING INSULIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL INSULIN MARKET SIZE, BY PREMIXED INSULIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL INSULIN MARKET SIZE, BY PREMIXED INSULIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL INSULIN MARKET SIZE, BY RAPID-ACTING INSULIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL INSULIN MARKET SIZE, BY RAPID-ACTING INSULIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL INSULIN MARKET SIZE, BY SHORT-ACTING INSULIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL INSULIN MARKET SIZE, BY SHORT-ACTING INSULIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL INSULIN MARKET SIZE, BY TYPE I DIABETES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL INSULIN MARKET SIZE, BY TYPE I DIABETES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL INSULIN MARKET SIZE, BY TYPE II DIABETES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL INSULIN MARKET SIZE, BY TYPE II DIABETES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. AMERICAS INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 32. AMERICAS INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 33. AMERICAS INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 34. AMERICAS INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 35. AMERICAS INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 36. AMERICAS INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 37. AMERICAS INSULIN MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 38. AMERICAS INSULIN MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 39. ARGENTINA INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 40. ARGENTINA INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 41. ARGENTINA INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 42. ARGENTINA INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 43. ARGENTINA INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 44. ARGENTINA INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 45. BRAZIL INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 46. BRAZIL INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 47. BRAZIL INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 48. BRAZIL INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 49. BRAZIL INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 50. BRAZIL INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 51. CANADA INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 52. CANADA INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 53. CANADA INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 54. CANADA INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 55. CANADA INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 56. CANADA INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 57. MEXICO INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 58. MEXICO INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 59. MEXICO INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 60. MEXICO INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 61. MEXICO INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 62. MEXICO INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 63. UNITED STATES INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 64. UNITED STATES INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 65. UNITED STATES INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 66. UNITED STATES INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 67. UNITED STATES INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 68. UNITED STATES INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 69. UNITED STATES INSULIN MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 70. UNITED STATES INSULIN MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC INSULIN MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC INSULIN MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 80. AUSTRALIA INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 82. AUSTRALIA INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 84. AUSTRALIA INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 85. CHINA INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 86. CHINA INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 87. CHINA INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 88. CHINA INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 89. CHINA INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 90. CHINA INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 91. INDIA INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 92. INDIA INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 93. INDIA INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 94. INDIA INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 95. INDIA INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 96. INDIA INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 97. INDONESIA INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 98. INDONESIA INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 99. INDONESIA INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 100. INDONESIA INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 101. INDONESIA INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 102. INDONESIA INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 103. JAPAN INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 104. JAPAN INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 105. JAPAN INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 106. JAPAN INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 107. JAPAN INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 108. JAPAN INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 109. MALAYSIA INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 110. MALAYSIA INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 111. MALAYSIA INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 112. MALAYSIA INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 113. MALAYSIA INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 114. MALAYSIA INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 116. PHILIPPINES INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 118. PHILIPPINES INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 120. PHILIPPINES INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 121. SINGAPORE INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 122. SINGAPORE INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 123. SINGAPORE INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 124. SINGAPORE INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 125. SINGAPORE INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 126. SINGAPORE INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 128. SOUTH KOREA INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 130. SOUTH KOREA INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 132. SOUTH KOREA INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 133. TAIWAN INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 134. TAIWAN INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 135. TAIWAN INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 136. TAIWAN INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 137. TAIWAN INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 138. TAIWAN INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 139. THAILAND INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 140. THAILAND INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 141. THAILAND INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 142. THAILAND INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 143. THAILAND INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 144. THAILAND INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 145. VIETNAM INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 146. VIETNAM INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 147. VIETNAM INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 148. VIETNAM INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 149. VIETNAM INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 150. VIETNAM INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA INSULIN MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA INSULIN MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 159. DENMARK INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 160. DENMARK INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 161. DENMARK INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 162. DENMARK INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 163. DENMARK INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 164. DENMARK INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 165. EGYPT INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 166. EGYPT INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 167. EGYPT INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 168. EGYPT INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 169. EGYPT INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 170. EGYPT INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 171. FINLAND INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 172. FINLAND INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 173. FINLAND INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 174. FINLAND INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 175. FINLAND INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 176. FINLAND INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 177. FRANCE INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 178. FRANCE INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 179. FRANCE INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 180. FRANCE INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 181. FRANCE INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 182. FRANCE INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 183. GERMANY INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 184. GERMANY INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 185. GERMANY INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 186. GERMANY INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 187. GERMANY INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 188. GERMANY INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 189. ISRAEL INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 190. ISRAEL INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 191. ISRAEL INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 192. ISRAEL INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 193. ISRAEL INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 194. ISRAEL INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 195. ITALY INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 196. ITALY INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 197. ITALY INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 198. ITALY INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 199. ITALY INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 200. ITALY INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 202. NETHERLANDS INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 204. NETHERLANDS INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 206. NETHERLANDS INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 207. NIGERIA INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 208. NIGERIA INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 209. NIGERIA INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 210. NIGERIA INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 211. NIGERIA INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 212. NIGERIA INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 213. NORWAY INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 214. NORWAY INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 215. NORWAY INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 216. NORWAY INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 217. NORWAY INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 218. NORWAY INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 219. POLAND INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 220. POLAND INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 221. POLAND INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 222. POLAND INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 223. POLAND INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 224. POLAND INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 225. QATAR INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 226. QATAR INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 227. QATAR INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 228. QATAR INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 229. QATAR INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 230. QATAR INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 231. RUSSIA INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 232. RUSSIA INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 233. RUSSIA INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 234. RUSSIA INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 235. RUSSIA INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 236. RUSSIA INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 238. SAUDI ARABIA INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 240. SAUDI ARABIA INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 242. SAUDI ARABIA INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 244. SOUTH AFRICA INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 246. SOUTH AFRICA INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 248. SOUTH AFRICA INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 249. SPAIN INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 250. SPAIN INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 251. SPAIN INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 252. SPAIN INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 253. SPAIN INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 254. SPAIN INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 255. SWEDEN INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 256. SWEDEN INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 257. SWEDEN INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 258. SWEDEN INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 259. SWEDEN INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 260. SWEDEN INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 262. SWITZERLAND INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 264. SWITZERLAND INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 265. SWITZERLAND INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 266. SWITZERLAND INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 267. TURKEY INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 268. TURKEY INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 269. TURKEY INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 270. TURKEY INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 271. TURKEY INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 272. TURKEY INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 277. UNITED ARAB EMIRATES INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 278. UNITED ARAB EMIRATES INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 280. UNITED KINGDOM INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 282. UNITED KINGDOM INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 284. UNITED KINGDOM INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 285. INSULIN MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 286. INSULIN MARKET, FPNV POSITIONING MATRIX, 2023